Global Communicable Diseases Treatment Market, Type (Sexually Transmitted Diseases, Helminthic Diseases, Contact Communicable Diseases, Oral Contamination Diseases, Air Borne Diseases), Indication (Gastroenteritis, Gonorrhoea, Whooping Cough, Common Cold, HIV/AIDS, Pink Eye, Hepatitis, Others), Treatment Type (Vaccine, Therapeutics, Others), Route of Administration (Oral, Parenteral, Others), Infectious Agent (Bacteria, Viruses, Fungi/Parasites), Mode of Transmission (Direct Contact, Indirect Contact), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
According to the World Health Organization (WHO), about 37.9 million people worldwide were infected with HIV in 2018. The majority of this prevalence is seen in poor and middle-income nations, with 66 percent of the population living in Sub-Saharan Africa. In 2016, around 6.3 million new cases of tuberculosis (TB) were reported, according to the WHO's 2017 Global Tuberculosis Report. As per the research, the new cases accounted for 61 percent of the anticipated 10.4 million cases of tuberculosis. Infectious agents such as fungi, viruses, bacteria, and parasites are the most common causes of communicable disorders.
Furthermore, some communicable diseases are transmitted by the air, contaminated food or beverages, contaminated surfaces, and blood or bodily fluids. A bite from an infected animal can also spread infectious disease. Some communicable diseases have relatively minor symptoms that go away on their own. Others may result in severe symptoms or life-threatening complications. Depending on the disease process and clinical appearance, patients require different treatments.
Data Bridge Market Research analyses that the communicable diseases treatment market was valued at USD 28.1 billion in 2021 and is expected to reach USD 47.0 billion by 2029, registering a CAGR of 6.64% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable to 2014 - 2019) |
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
Segments Covered |
Type (Sexually Transmitted Diseases, Helminthic Diseases, Contact Communicable Diseases, Oral Contamination Diseases, Air Borne Diseases), Indication (Gastroenteritis, Gonorrhoea, Whooping Cough, Common Cold, HIV/AIDS, Pink Eye, Hepatitis, Others), Treatment Type (Vaccine, Therapeutics, Others), Route of Administration (Oral, Parenteral, Others), Infectious Agent (Bacteria, Viruses, Fungi/Parasites), Mode of Transmission (Direct Contact, Indirect Contact), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Endo International plc (Ireland), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (U.S.), Fresenius Kabi AG (Germany), Torrent Pharmaceuticals Ltd. (India) |
Market Opportunities |
|
Market Definition
A communicable disease is one that can be passed from person to person or animal to animal. These diseases are caused by pathogens including viruses, bacteria, and fungus. Vaccines are a powerful tool for preventing viral diseases. Antibiotics may be needed to treat a bacterial infections. These drugs can help kill bacteria or slow them down enough that the immune system can fight them off. Antifungal prescriptions and, in rare situations, intravenous medicine may be required for a severe or chronic fungal infection. Over-the-counter topical ointments can be used to treat various benign diseases such as ringworm and athlete's foot.
Communicable Diseases Treatment Market Dynamics
Drivers
- Rising incidences of infectious diseases
The rising incidences of infectious diseases such as hepatitis, diphtheria, and Lyme disease will act as a major driver that will expand the growth rate of the market. According to the Centers for Disease Control and Prevention, in 2016 and 2017, there were 0.62 and 1.03 new cases of communicable disease per 100,000 people in the United States, respectively.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of communicable diseases treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Increasing number of geriatric population
The increasing number of geriatric population is estimated to enhance the market's growth rate. According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. The proportion of the geriatric population is estimated to rise. The elderly population is expected to grow, and this will enhance the market's growth rate as they are more prone to communicable diseases.
Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will expand the communicable diseases treatment market. Along with this, rising level of disposable income and growing government favorable initiatives will enhance the market's growth rate.
Opportunities
- Rise in R&D activities
The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the communicable diseases treatment market growth. Antibiotic overuse leads to microbial resistance. As a result, the global market is projected to be propelled by the launch of innovative therapies and products. Players in the industry are working on new goods and investing in research and development. For instance, Merck Sharp & Dohme Corp is one of the market's major competitors, with an aggressive research and development program aimed at addressing unmet medical needs in the prevention and treatment of infectious disease.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the communicable diseases treatment market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of the communicable diseases treatment market during 2022-2029. The lack of healthcare infrastructure in developing economies and patent expiration will challenge the communicable diseases treatment market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This communicable diseases treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the communicable diseases treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Communicable diseases treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Communicable Diseases Treatment Market
The COVID-19 pandemic had a negative influence on most companies' overall sales, but it had a favourable impact on the infectious disease diagnostics industry since infectious disease diagnostic procedures were used for COVID-19 testing. People postponed health checkups as a result of the COVID-19 epidemic, reducing the number of tests performed and reagent sales. However, as governments gradually loosen travel restrictions, testing numbers are expected to rise again. With the COVID-19 pandemic, dealing with infectious disease has become a major medical concern all around the world. Apart from vaccinations and therapeutic medications, there is a growing demand for more precise and simple testing technologies and the expansion of testing structures. As governments and healthcare providers face unprecedented problems, COVID-19 had an impact on the regulatory environment and practices. Regulatory agencies used a variety of techniques to expedite the approval of diagnostic products. Companies have made strategic decisions to implement COVID-19 rapid tests, maintain revenue, and mitigate COVID-19's impact on their operating capabilities.
Recent Development
- In December 2021, Roche announced the launch of first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. Cobas HBV, cobas HIV-1, cobas HIV-1/HIV-2 Qualitative, cobas HCV, and the cobas omni Utility Channel kit are some of them. These new products broaden Roche Molecular's range by delivering consistent performance and efficiency for low, medium, and high volume molecular laboratory testing.
Global Communicable Diseases Treatment Market Scope
The communicable diseases treatment market is segmented on the basis of indication, type, treatment type, infectious agent, mode of transmission, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Gastroenteritis
- Gonorrhoea
- Whooping Cough
- Common Cold
- HIV/AIDS
- Pink Eye
- Hepatitis
- Others
Treatment Type
- Vaccine
- Therapeutics
- Antibiotics
- Antivirals
- Antifungal
- Antiparasitics
- Others
- Others
Infectious Agent
- Bacteria
- Viruses
- Fungi/Parasites
Mode of Transmission
- Direct Contact
- Person-to-person Contact
- Droplet Spread
- Others
- Indirect Contact
- Airborne Transmission
- Contaminated Objects
- Food and Drinking Water
- Others
Type
- Sexually Transmitted Diseases
- Helminthic Diseases
- Contact Communicable Diseases
- Oral Contamination Diseases
- Air Borne Diseases
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Communicable Diseases Treatment Market Regional Analysis/Insights
The communicable diseases treatment market is analyzed and market size insights and trends are provided by country, indication, type, treatment type, infectious agent, mode of transmission, route of administration, end-users and distribution channel as referenced above.
The countries covered in the communicable diseases treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America and Europe dominate the communicable diseases treatment market because of the rising healthcare expenditure and vulnerable AIDS population in this region. Additionally, the growing focus of major key players in research and development activities will further propel the market's growth rate.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Communicable Diseases Treatment Market Share Analysis
The communicable diseases treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to communicable diseases treatment market.
Some of the major players operating in the communicable diseases treatment market are:
- Eli Lilly and Company (U.S.)
- AstraZeneca (U.K.)
- Novartis AG (Switzerland)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- Bausch Health Companies Inc. (Canada)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Sanofi (France)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Endo International plc (Ireland)
- Apotex Inc. (Canada)
- Amneal Pharmaceuticals LLC. (U.S.)
- Fresenius Kabi AG (Germany)
- Torrent Pharmaceuticals Ltd. (India)
SKU-